7932 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • compound  (SPT Labtech)
    93
    SPT Labtech compound
    Compound, supplied by SPT Labtech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compound/product/SPT Labtech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    compound - by Bioz Stars, 2023-03
    93/100 stars
    		  Buy from Supplier
    pathscan akt signaling antibody array kit  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc pathscan akt signaling antibody array kit
    cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of <t>Akt</t> signaling in mouse hearts. a. Heat map from <t>PathScan®</t> Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).
    Pathscan Akt Signaling Antibody Array Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan akt signaling antibody array kit/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathscan akt signaling antibody array kit - by Bioz Stars, 2023-03
    90/100 stars
    		  Buy from Supplier
    14 atcc  (ATCC)
    90
    ATCC 14 atcc
    cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of <t>Akt</t> signaling in mouse hearts. a. Heat map from <t>PathScan®</t> Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).
    14 Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/14 atcc/product/ATCC
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    14 atcc - by Bioz Stars, 2023-03
    90/100 stars
    		  Buy from Supplier
    queensland compound library  (SPT Labtech)
    86
    SPT Labtech queensland compound library
    cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of <t>Akt</t> signaling in mouse hearts. a. Heat map from <t>PathScan®</t> Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).
    Queensland Compound Library, supplied by SPT Labtech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/queensland compound library/product/SPT Labtech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    queensland compound library - by Bioz Stars, 2023-03
    86/100 stars
    		  Buy from Supplier
    apexii diffractometer 7932  (Bruker Corporation)
    86
    Bruker Corporation apexii diffractometer 7932
    cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of <t>Akt</t> signaling in mouse hearts. a. Heat map from <t>PathScan®</t> Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).
    Apexii Diffractometer 7932, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apexii diffractometer 7932/product/Bruker Corporation
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    apexii diffractometer 7932 - by Bioz Stars, 2023-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of Akt signaling in mouse hearts. a. Heat map from PathScan® Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).

    Journal: EBioMedicine

    Article Title: Cardiac troponin I autoantibody induces myocardial dysfunction by PTEN signaling activation

    doi: 10.1016/j.ebiom.2019.08.045

    Figure Lengend Snippet: cTnImAb1 treatment increases ENO1 expression followed by activation of PTEN and suppression of Akt signaling in mouse hearts. a. Heat map from PathScan® Akt Signaling Antibody Array kit analysis showing changes in 16 phosphorylated proteins. b & c. Statistical analysis of heat map data in a and volcano plot showing that cTnImAb1 treatment significantly increased PTEN Ser380 phosphorylation in the mouse heart. 1. PTEN Ser380, *p = .023, ( t -test). 2. GSK-3b Ser9, * p = .038, ( t -test). 3. PTEN Ser380, * p = .031 ( t -test). d&e. Immunoblot analysis showed that cTnImAb1 treatment significantly increased ENO1 expression and PTEN Ser380 phosphorylation but suppressed Akt Thr308 phosphorylation. β-actin served as a loading control. e is the statistical analysis of d . ENO1 * p = .002, pPTEN/PTEN/Actin, * p = .003, pAkt/Akt/Actin, * p = .003. (ANOVA analysis). f-h. cTnImAb1 treatment (50 μg/ml) induced changes in ENO1 expression and phosphorylation of PTEN Ser380 and Akt Thr308 at different time points in cultured cardiomyoyctes. cTnImAb1 increased the p-Ser380-PTEN/total PTEN ratio at 8 h but decreased the pThr308-AKT/total Akt ratio at 8–12 h. Mouse IgG treatment did not alter pSer380 PTEN but significantly increased the pThr308-Akt/total Akt ratio at 24–36 h. f shows representative blot images of three independent experiments. g and h represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( G, 8 h * p = .020, 12 h * p = .024, t -test) and pThr308-AKT/total Akt ( H , 12 h * p = .018, 24 h * p = .001, 36 h * p = .001, t -test). i-l. Knockdown of ENO1 significantly suppressed cTnImAb1–induced alteration in PTEN/Akt signaling. Cultured cardiomyocytes were transfected with siRNA targeting Eno1 and then subjected to cTnImAb1 treatment (50 μg/ml) for 4–48 h as indicated. Mock-siRNA was used as a control. Depletion of Eno1 suppressed the p-PTEN Ser380/total PTEN ratio and increased the pAkt-Thr308/total Akt ratio at 4, 8, and 12 h, respectively. i shows representative blot images of three independent experiments. j represents ImageJ-based densitometry analysis of relative changes in ENO1 protein levels ( J ,48 h * p = .000, t -test). k and l represent ImageJ-based densitometry analysis of relative changes in p-Ser380-PTEN/total PTEN ratio ( k, 48 h * p = .000, t -test) and pThr308-AKT/total Akt ( l, 6 h * p = .000, 12 h * p = .000, t -test).

    Article Snippet: Mouse cardiac tissue total protein Akt signaling was screened using the PathScan® Akt Signaling Antibody Array Kit (Cell Signal, 9474, USA).

    Techniques: Expressing, Activation Assay, Ab Array, Western Blot, Cell Culture, Transfection